Type I interferons protect mice against enterovirus 71 infection Free

Abstract

In this study, the contribution of type I interferons (IFNs) to protection against infection with enterovirus 71 (EV71) was investigated using a murine model where the virus was administrated to neonatal Institute of Cancer Research (ICR) mice by either the intraperitoneal (i.p.) or the oral route. In i.p. inoculated mice, post-infection treatment of dexamethasone (5 mg kg at 2 or 3 days after infection) exacerbated clinical symptoms and increased the tissue viral titre. In contrast, polyriboinosinic : polyribocytidylic acid [poly(I : C); 10 or 100 μg per mouse at 12 h before infection], a potent IFN inducer, improved the survival rate and decreased the tissue viral titres after EV71 challenge, which correlated with an increase in serum IFN- concentration, the percentage of dendritic cells, their expression of major histocompatibility complex class II molecule and IFN- in spleen. Treatment with a neutralizing antibody for type I IFNs (10 neutralizing units per mouse, 6 h before and 12 h after infection) resulted in frequent deaths and higher tissue viral load in infected mice compared with control mice. In contrast, an early administration of recombinant mouse IFN-A (10 U per mouse for 3 days starting at 0, 1 or 3 days after infection) protected the mice against EV71 infection. analysis of virus-induced death in three human cell lines showed that human type I IFNs exerted a direct protective effect on EV71. It was concluded that type I IFNs play an important role in controlling EV71 infection and replication.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81195-0
2005-12-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/12/3263.html?itemId=/content/journal/jgv/10.1099/vir.0.81195-0&mimeType=html&fmt=ahah

References

  1. Chang L.-Y., Lin T.-Y., Hsu K.-H. 8 other authors 1999; Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354:1682–1686 [CrossRef]
    [Google Scholar]
  2. Chang L.-Y., Hsia S.-H., Wu C.-T., Huang Y.-C., Lin K.-L., Fang T.-Y., Lin T.-Y. 2004; Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J 23:327–332 [CrossRef]
    [Google Scholar]
  3. Chaudhuri A. 2004; Adjunctive dexamethasone treatment in acute bacterial meningitis. Lancet Neurol 3:54–62 [CrossRef]
    [Google Scholar]
  4. Goodbourn S., Didcock L., Randall R. E. 2000; Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81:2341–2364
    [Google Scholar]
  5. Guggenheim M. A., Baron S. 1977; Clinical studies of an interferon inducer, polyriboinosinic-polyribocytidylic acid [poly(I)-poly(C)], in children. J Infect Dis 136:50–58 [CrossRef]
    [Google Scholar]
  6. Ho M., Chen E.-R., Hsu K.-H., Twu S.-J., Chen K.-T., Tsai S.-F., Wang J.-R., Shih S.-R. 1999; An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341:929–935 [CrossRef]
    [Google Scholar]
  7. Hsiung G. D. 1994; Virus assay, neutralization test and antiviral assay. In Hsiung's Diagnostic Virology pp  46–55 Edited by Hsiung G. D., Fong C. K. Y., Landry M. L. New Haven: Yale University Press;
    [Google Scholar]
  8. Huang C.-C., Liu C.-C., Chang Y.-C., Chen C.-Y., Wang S.-T., Yeh T.-F. 1999; Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341:936–942 [CrossRef]
    [Google Scholar]
  9. Kirkwood J. 2002; Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29:18–26 [CrossRef]
    [Google Scholar]
  10. Komatsu H., Shimizu Y., Takeuchi Y., Ishiko H., Takada H. 1999; Outbreak of severe neurologic involvement associated with enterovirus 71 infection. Pediatr Neurol 20:17–23 [CrossRef]
    [Google Scholar]
  11. Kunzmann V., Kretzschmar E., Herrmann T., Wilhelm M. 2004; Polyinosinic-polycytidylic acid-mediated stimulation of human γδ T cells via CD11c dendritic cell-derived type I interferons. Immunology 112:369–377 [CrossRef]
    [Google Scholar]
  12. Lin T.-Y., Chang L.-Y., Hsia S.-H., Huang Y.-C., Chiu C.-H., Hsueh C., Shih S.-R., Liu C. C., Wu M.-H. 2002a; The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis 34:S52–S57 [CrossRef]
    [Google Scholar]
  13. Lin T.-Y., Chang L.-Y., Huang Y.-C., Hsu K.-H., Chiu C.-H., Yang K.-D. 2002b; Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr 91:632–635 [CrossRef]
    [Google Scholar]
  14. Lin T.-Y., Hsia S.-H., Huang Y.-C., Wu C.-T., Chang L.-Y. 2003; Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 36:269–274 [CrossRef]
    [Google Scholar]
  15. Lum L.-C., Wong K.-T., Lam S.-K. 7 other authors 1998; Fatal enterovirus 71 encephalomyelitis. J Pediatr 133:795–798 [CrossRef]
    [Google Scholar]
  16. McMinn P. C. 2002; An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91–107 [CrossRef]
    [Google Scholar]
  17. Nolan M. A., Craig M. E., Lahra M. M., Rawlinson W. D., Prager P. C., Williams G. D., Bye A. M., Andrews P. I. 2003; Survival after pulmonary edema due to enterovirus 71 encephalitis. Neurology 60:1651–1656 [CrossRef]
    [Google Scholar]
  18. Padalko E., Nuyens D., de Palma A., Verbeken E., Aerts J. L., de Clercq E., Carmeliet P., Neyts J. 2004; The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 48:267–274 [CrossRef]
    [Google Scholar]
  19. Poast J., Seidel H. M., Hendricks M. D., Haslam J. A., Levy H. B., Baron S. 2002; Poly I: CLC induction of the interferon system in mice: an initial study of four detection methods. J Interferon Cytokine Res 22:1035–1040 [CrossRef]
    [Google Scholar]
  20. Pyo S., Gangemi J. D., Ghaffar A., Mayer E. P. 1993; Poly I: C-induced antiviral and cytotoxic activities are mediated by different mechanisms. Int J Immunopharmacol 15:477–486 [CrossRef]
    [Google Scholar]
  21. Sasaki O., Karaki T., Imanishi J. 1986; Protective effect of interferon on infections with hand, foot, and mouth disease virus in newborn mice. J Infect Dis 153:498–502 [CrossRef]
    [Google Scholar]
  22. Schmidt K. N., Leung B., Kwong M., Zarember K. A., Satyal S., Navas T. A., Wang F., Godowski P. J. 2004; APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol 172:138–143 [CrossRef]
    [Google Scholar]
  23. Sommer J. B., Heckmann J. G., Kraus J., Neundorfer B., Erbguth F. J. 2000; Generalized brain edema in non-purulent meningoencephalitis. The anti-edema effect of therapy with dexamethasone. Nervenarzt 71:112–115 [CrossRef]
    [Google Scholar]
  24. Wang S.-M., Liu C.-C., Tseng H.-W., Wang J.-R., Huang C.-C., Chen Y.-J., Yang Y.-J., Lin S.-J., Yeh T.-F. 1999; Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 29:184–190 [CrossRef]
    [Google Scholar]
  25. Wang S.-M., Lei H.-Y., Huang K.-J., Wu J.-M., Wang J.-R., Yu C.-K., Su I.-J., Liu C.-C. 2003; Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 188:564–570 [CrossRef]
    [Google Scholar]
  26. Wang Y.-F., Chou C.-T., Lei H.-Y. 8 other authors 2004; A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78:7916–7924 [CrossRef]
    [Google Scholar]
  27. Wu C.-K., Lin Y.-C., Fann C., Liao N.-S., Shin S.-R., Ho M.-S. 2002; Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895–904
    [Google Scholar]
  28. Yan J.-J., Wang J.-R., Liu C.-C., Yang H.-B., Su I.-J. 2000; An outbreak of enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J Clin Virol 17:13–22 [CrossRef]
    [Google Scholar]
  29. Yan J.-J., Su I.-J., Chen P.-F., Liu C.-C., Yu C.-K., Wang J.-R. 2001; Complete genome analysis of enterovirus 71 isolated from an outbreak in Taiwan and rapid identification of enterovirus 71 and coxsackievirus A16 by RT-PCR. J Med Virol 65:331–339 [CrossRef]
    [Google Scholar]
  30. Yang K.-D., Yang M.-Y., Li C.-C., Lin S.-F., Chong M.-C., Wang C.-L., Chen R.-F., Lin T.-Y. 2001; Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis 183:850–856 [CrossRef]
    [Google Scholar]
  31. Yu C.-K., Chen C.-C., Chen C.-L., Wang J.-R., Liu C.-C., Yan J.-J., Su I.-J. 2000; Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7:523–528 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81195-0
Loading
/content/journal/jgv/10.1099/vir.0.81195-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed